依那西普改善银屑病患者的健康相关生活质量：一项III期随机临床试验的结果。
Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.
作者信息
Feldman Steven R, Kimball Alexa Boer, Krueger Gerald G, Woolley J Michael, Lalla Deepa, Jahreis Angelika
机构信息
Wake Forest University School of Medicine, Winston Salem, North Carolina 27157-1071, USA.
出版信息
J Am Acad Dermatol. 2005 Nov;53(5):887-9. doi: 10.1016/j.jaad.2005.06.053.
In this randomized, double-blind, phase III trial, patients with psoriasis received etanercept for 24 weeks or placebo for 12 weeks followed by etanercept for 12 weeks. At week 12, improvement in Dermatology Life Quality Index was 47% to 61% with etanercept compared with 11% with placebo (P < .0001). Etanercept rapidly and substantially improved patients' health-related quality of life.
在这项随机、双盲、III期试验中，银屑病患者接受了24周的依那西普治疗，或先接受12周的安慰剂治疗，随后再接受12周的依那西普治疗。在第12周时，与安慰剂组11%的改善率相比，依那西普组皮肤病生活质量指数的改善率为47%至61%（P <.0001）。依那西普迅速且显著地改善了患者与健康相关的生活质量。
Zotero 插件